Literature DB >> 32293756

A flexible nonlinear mixed effects model for HIV viral load rebound after treatment interruption.

Rui Wang1,2, Ante Bing2, Cathy Wang2, Yuchen Hu2, Ronald J Bosch2, Victor DeGruttola2.   

Abstract

Characterization of HIV viral rebound after the discontinuation of antiretroviral therapy is central to HIV cure research. We propose a parametric nonlinear mixed effects model for the viral rebound trajectory, which often has a rapid rise to a peak value followed by a decrease to a viral load set point. We choose a flexible functional form that captures the shapes of viral rebound trajectories and can also provide biological insights regarding the rebound process. Each parameter can incorporate a random effect to allow for variation in parameters across individuals. Key features of viral rebound trajectories such as viral set points are represented by the parameters in the model, which facilitates assessment of intervention effects and identification of important pretreatment interruption predictors for these features. We employ a stochastic expectation-maximization (StEM) algorithm to incorporate HIV-1 RNA values that are below the lower limit of assay quantification. We evaluate the performance of our model in simulation studies and apply the proposed model to longitudinal HIV-1 viral load data from five AIDS Clinical Trials Group treatment interruption studies.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  censoring; imputation; iterative; nonlinear; viral rebound

Mesh:

Substances:

Year:  2020        PMID: 32293756      PMCID: PMC8081565          DOI: 10.1002/sim.8529

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  33 in total

1.  Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission.

Authors:  Roland Tubiana; Jade Ghosn; Marcio De-Sa; Marc Wirden; Agnès Gautheret-Dejean; François Bricaire; Christine Katlama
Journal:  AIDS       Date:  2002-05-03       Impact factor: 4.177

2.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

3.  Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial.

Authors:  Marie-Anne Bouldouyre; Isabelle Charreau; Bruno Marchou; Philippe Tangre; Christine Katlama; Philippe Morlat; Vincent Meiffredy; Daniel Vittecoq; Philippe Bierling; Jean-Pierre Aboulker; Jean-Michel Molina
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

Review 4.  Posttreatment controllers: what do they tell us?

Authors:  Christine Rouzioux; Laurent Hocqueloux; Asier Sáez-Cirión
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

5.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Authors:  Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

6.  General right censoring and its impact on the analysis of survival data.

Authors:  S W Lagakos
Journal:  Biometrics       Date:  1979-03       Impact factor: 2.571

7.  AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.

Authors:  Robert T Schooley; John Spritzler; Hongying Wang; Michael M Lederman; Diane Havlir; Daniel R Kuritzkes; Richard Pollard; Cathy Battaglia; Michael Robertson; Devan Mehrotra; Danilo Casimiro; Kara Cox; Barbara Schock
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

8.  Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment.

Authors:  Paul Volberding; Lisa Demeter; Ronald J Bosch; Evgenia Aga; Carla Pettinelli; Martin Hirsch; Mary Vogler; Ana Martinez; Susan Little; Elizabeth Connick
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

9.  Immunological biomarkers predict HIV-1 viral rebound after treatment interruption.

Authors:  Jacob Hurst; Matthias Hoffmann; Matthew Pace; James P Williams; John Thornhill; Elizabeth Hamlyn; Jodi Meyerowitz; Chris Willberg; Kersten K Koelsch; Nicola Robinson; Helen Brown; Martin Fisher; Sabine Kinloch; David A Cooper; Mauro Schechter; Giuseppe Tambussi; Sarah Fidler; Abdel Babiker; Jonathan Weber; Anthony D Kelleher; Rodney E Phillips; John Frater
Journal:  Nat Commun       Date:  2015-10-09       Impact factor: 14.919

10.  Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.

Authors:  Erica N Borducchi; Jinyan Liu; Joseph P Nkolola; Anthony M Cadena; Wen-Han Yu; Stephanie Fischinger; Thomas Broge; Peter Abbink; Noe B Mercado; Abishek Chandrashekar; David Jetton; Lauren Peter; Katherine McMahan; Edward T Moseley; Elena Bekerman; Joseph Hesselgesser; Wenjun Li; Mark G Lewis; Galit Alter; Romas Geleziunas; Dan H Barouch
Journal:  Nature       Date:  2018-10-03       Impact factor: 49.962

View more
  3 in total

1.  Nonlinear mixed-effects models for HIV viral load trajectories before and after antiretroviral therapy interruption, incorporating left censoring.

Authors:  Sihaoyu Gao; Lang Wu; Tingting Yu; Roger Kouyos; Huldrych F Günthard; Rui Wang
Journal:  Stat Commun Infect Dis       Date:  2022-04-04

2.  Comparison of empirical and dynamic models for HIV viral load rebound after treatment interruption.

Authors:  Ante Bing; Yuchen Hu; Melanie Prague; Alison L Hill; Jonathan Z Li; Ronald J Bosch; Victor De Gruttola; Rui Wang
Journal:  Stat Commun Infect Dis       Date:  2020-08-21

Review 3.  Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.

Authors:  Lu Zheng; Camlin Tierney; Ronald J Bosch
Journal:  Curr HIV/AIDS Rep       Date:  2021-07-02       Impact factor: 5.495

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.